InsiderTrades.com logo
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.

NAMS Insider Trading

Insider Ownership Percentage: 19.50%
Insider Buying (Last 12 Months): $379,856.30
Insider Selling (Last 12 Months): $4,802,634.00

NewAmsterdam Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at NewAmsterdam Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NewAmsterdam Pharma Share Price & Price History

Current Price: $24.90
Price Change: ▼ Price Decrease of -0.07 (-0.28%)
As of 11/15/2024 01:00 AM ET

This chart shows the closing price history over time for NAMS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
I was wrong. Dead wrong.
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.

NewAmsterdam Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2024Louise Frederika KooijCAOSell45,000$15.72$707,400.00View SEC Filing Icon  
9/26/2024Juliette Berangere AudetInsiderBuy1,104$15.70$17,332.801,104View SEC Filing Icon  
6/20/2024Michael H DavidsonCEOBuy5,000$17.26$86,300.00204,784View SEC Filing Icon  
3/26/2024James N TopperDirectorBuy8,429$21.50$181,223.503,008,429View SEC Filing Icon  
3/26/2024Johannes Jacob Piete KasteleinInsiderSell190,476$21.50$4,095,234.00View SEC Filing Icon  
2/13/2024Louis G LangeDirectorBuy5,000$19.00$95,000.0024,878View SEC Filing Icon  
See Full Table
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.

SEC Filings (Institutional Ownership Changes) for NewAmsterdam Pharma (NASDAQ:NAMS)

89.89% of NewAmsterdam Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NAMS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

NewAmsterdam Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2024XTX Topco Ltd11,265$0.19M0.0%N/A0.013%Search for SEC Filing on Google Icon
11/15/2024Wellington Management Group LLP92,223$1.53M0.0%+11.0%0.102%Search for SEC Filing on Google Icon
11/15/2024State Street Corp37,915$0.63M0.0%+168.7%0.042%Search for SEC Filing on Google Icon
11/15/2024Quarry LP6,500$0.11M0.0%+2,469.2%0.007%Search for SEC Filing on Google Icon
11/15/2024Readystate Asset Management LP121,000$2.01M0.0%N/A0.134%Search for SEC Filing on Google Icon
11/15/2024Parkman Healthcare Partners LLC105,334$1.75M0.2%-22.2%0.117%Search for SEC Filing on Google Icon
11/15/2024Janus Henderson Group PLC1,540,729$25.61M0.0%+51.1%1.712%Search for SEC Filing on Google Icon
11/15/2024Cinctive Capital Management LP66,571$1.11M0.1%+77.7%0.074%Search for SEC Filing on Google Icon
11/15/2024ArrowMark Colorado Holdings LLC354,975$5.89M0.1%+19.5%0.394%Search for SEC Filing on Google Icon
11/14/2024Bellevue Group AG7,700$0.13M0.0%N/A0.009%Search for SEC Filing on Google Icon
11/14/2024Walleye Capital LLC46,947$0.78M0.0%N/A0.052%Search for SEC Filing on Google Icon
11/14/2024UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC239,283$3.97M0.0%+1,231.0%0.266%Search for SEC Filing on Google Icon
11/13/2024FMR LLC330,412$5.49M0.0%+35.6%0.367%Search for SEC Filing on Google Icon
11/12/2024HealthInvest Partners AB138,983$2.31M1.1%+83.4%0.154%Search for SEC Filing on Google Icon
11/8/2024Jennison Associates LLC1,020,278$16.94M0.0%+8.9%1.133%Search for SEC Filing on Google Icon
11/5/2024GSA Capital Partners LLP66,402$1.10M0.1%+79.9%0.074%Search for SEC Filing on Google Icon
11/4/2024Lisanti Capital Growth LLC42,165$0.70M0.2%N/A0.047%Search for SEC Filing on Google Icon
11/4/2024Wolverine Asset Management LLC4,944$82K0.0%-68.2%0.005%Search for SEC Filing on Google Icon
11/4/2024TimesSquare Capital Management LLC255,245$4.24M0.1%+3.7%0.284%Search for SEC Filing on Google Icon
10/25/2024abrdn plc129,060$2.14M0.0%+69.8%0.143%Search for SEC Filing on Google Icon
10/23/2024Moody Aldrich Partners LLC216,493$3.59M0.7%-1.9%0.241%Search for SEC Filing on Google Icon
10/21/2024Venture Visionary Partners LLC10,000$0.17M0.0%-9.1%0.011%Search for SEC Filing on Google Icon
8/15/2024Millennium Management LLC1,165,429$22.39M0.0%+23.0%1.295%Search for SEC Filing on Google Icon
8/15/2024Deerfield Management Company L.P. Series C869,250$16.70M0.3%+30.3%0.966%Search for SEC Filing on Google Icon
8/15/2024Decheng Capital LLC400,000$7.68M2.4%N/A0.445%Search for SEC Filing on Google Icon
8/15/2024Affinity Asset Advisors LLC423,155$8.13M0.9%+47.9%0.470%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP21,831$0.42M0.0%-81.1%0.024%Search for SEC Filing on Google Icon
8/13/2024Sei Investments Co.24,561$0.47M0.0%+49.1%0.027%Search for SEC Filing on Google Icon
8/2/2024Wolverine Asset Management LLC15,524$0.30M0.0%+117.7%0.017%Search for SEC Filing on Google Icon
7/31/2024Banque Cantonale Vaudoise2,000$38K0.0%N/A0.002%Search for SEC Filing on Google Icon
7/12/2024Rosalind Advisors Inc.10,123$0.19M0.1%N/A0.011%Search for SEC Filing on Google Icon
5/29/2024Opaleye Management Inc.315,388$7.46M1.6%+18.8%0.351%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.800,000$18.92M0.5%N/A0.896%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC636,231$15.02M0.0%N/A0.713%Search for SEC Filing on Google Icon
5/15/2024Baker BROS. Advisors LP96,827$2.29M0.0%N/A0.108%Search for SEC Filing on Google Icon
5/15/2024Affinity Asset Advisors LLC286,200$6.77M0.8%+129.0%0.321%Search for SEC Filing on Google Icon
5/14/2024StemPoint Capital LP80,334$1.90M0.5%N/A0.090%Search for SEC Filing on Google Icon
5/7/2024TimesSquare Capital Management LLC228,616$5.41M0.1%N/A0.256%Search for SEC Filing on Google Icon
5/2/2024Jennison Associates LLC930,851$22.02M0.0%N/A1.043%Search for SEC Filing on Google Icon
4/10/2024Yarbrough Capital LLC23,960$0.57M0.0%N/A0.027%Search for SEC Filing on Google Icon
3/7/2024Fcpm Iii Services B.V.11,831,461$132.16M39.2%N/A14.373%Search for SEC Filing on Google Icon
2/15/2024Opaleye Management Inc.265,388$2.96M0.8%N/A0.325%Search for SEC Filing on Google Icon
2/15/2024Parkman Healthcare Partners LLC300,750$3.36M0.5%+20.8%0.369%Search for SEC Filing on Google Icon
2/1/2024Wolverine Asset Management LLC8,694$97K0.0%+197.2%0.011%Search for SEC Filing on Google Icon
11/15/2023Affinity Asset Advisors LLC125,000$1.16M0.3%+25.0%0.153%Search for SEC Filing on Google Icon
11/14/2023Schonfeld Strategic Advisors LLC64,700$0.60M0.0%+12.9%0.079%Search for SEC Filing on Google Icon
11/13/2023Wolverine Asset Management LLC2,925$27K0.0%N/A0.004%Search for SEC Filing on Google Icon
8/21/2023Affinity Asset Advisors LLC100,000$1.19M0.4%N/A0.123%Search for SEC Filing on Google Icon
8/15/2023RA Capital Management L.P.9,000,000$107.01M2.0%+125.0%11.035%Search for SEC Filing on Google Icon
8/15/2023Bain Capital Life Sciences Investors LLC10,473,913$124.54M12.8%+26.2%12.842%Search for SEC Filing on Google Icon
8/10/2023Monashee Investment Management LLC95,000$1.13M0.3%N/A0.116%Search for SEC Filing on Google Icon
8/4/2023Maven Securities LTD25,000$0.30M0.0%N/A0.031%Search for SEC Filing on Google Icon
7/19/2023Medicxi Ventures Management Jersey Ltd2,869,565$34.12M9.6%+43.5%3.518%Search for SEC Filing on Google Icon
7/14/2023Venture Visionary Partners LLC10,000$0.12M0.0%N/A0.012%Search for SEC Filing on Google Icon
5/9/2023GMT Capital Corp1,083,800$14.37M0.6%+8.4%6.106%Search for SEC Filing on Google Icon
5/8/2023Wolverine Asset Management LLC4,819$64K0.0%N/A0.027%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.4,000,000$43.60M0.9%N/A22.535%Search for SEC Filing on Google Icon
2/3/2023Frazier Life Sciences Management L.P.9,341,551$101.82M6.3%N/A52.628%Search for SEC Filing on Google Icon
2/3/2023GMT Capital Corp1,000,000$10.90M0.5%N/A5.634%Search for SEC Filing on Google Icon
1/31/2023Medicxi Ventures Management Jersey Ltd2,000,000$21.80M9.2%N/A11.268%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More on NewAmsterdam Pharma

Today's Range

Now: $24.90
Low: $24.50
High: $25.16

50 Day Range

MA: $18.35
Low: $15.24
High: $24.97

52 Week Range

Now: $24.90
Low: $8.90
High: $26.35

Volume

891,907 shs

Average Volume

270,394 shs

Market Capitalization

$2.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of NewAmsterdam Pharma?

NewAmsterdam Pharma's top insider shareholders include:
  1. James N Topper (Director)
  2. Michael H Davidson (CEO)
  3. Louis G Lange (Director)
  4. Juliette Berangere Audet (Insider)
  5. Johannes Jacob Piete Kastelein (Insider)
  6. Louise Frederika Kooij (CAO)
Learn More about top insider investors at NewAmsterdam Pharma.

Who are the major institutional investors of NewAmsterdam Pharma?

NewAmsterdam Pharma's top institutional shareholders include:
  1. Frazier Life Sciences Management L.P. — 14.28%
  2. Janus Henderson Group PLC — 1.71%
  3. Jennison Associates LLC — 1.13%
  4. ArrowMark Colorado Holdings LLC — 0.39%
  5. FMR LLC — 0.37%
  6. TimesSquare Capital Management LLC — 0.28%
Learn More about top institutional investors of NewAmsterdam Pharma stock.

Which institutional investors are selling NewAmsterdam Pharma stock?

In the previous quarter, NAMS stock was sold by these institutional investors:
  1. Parkman Healthcare Partners LLC
  2. Wolverine Asset Management LLC
  3. Moody Aldrich Partners LLC
  4. Venture Visionary Partners LLC
In the last year, company insiders that have sold NewAmsterdam Pharma company stock include:
  1. James N Topper (Director)
  2. Michael H Davidson (CEO)
Learn More investors selling NewAmsterdam Pharma stock.

Which institutional investors are buying NewAmsterdam Pharma stock?

Within the previous quarter, NAMS stock was bought by institutional investors including:
  1. Frazier Life Sciences Management L.P.
  2. Janus Henderson Group PLC
  3. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
  4. Readystate Asset Management LP
  5. FMR LLC
  6. Jennison Associates LLC
  7. HealthInvest Partners AB
  8. ArrowMark Colorado Holdings LLC
Within the last year, these company insiders have bought NewAmsterdam Pharma stock:
  1. James N Topper (Director)
  2. Michael H Davidson (CEO)
  3. Louis G Lange (Director)
  4. Juliette Berangere Audet (Insider)
Learn More investors buying NewAmsterdam Pharma stock.
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.